Rheumatology International

, Volume 30, Issue 1, pp 69–74

DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren syndrome and healthy subjects

  • Salima Belguith-Maalej
  • Hassen Hadj-Kacem
  • Neila Kaddour
  • Zouhir Bahloul
  • Hammadi Ayadi
Original Article

Abstract

Autoimmune diseases (AID) are caused by the loss of immunological tolerance against self-antigens. The deoxyribonuclease I (DNASE1) gene seems to participate in the genetic susceptibility of some AID. In fact, two mutations were reported among systemic lupus erythematosus (SLE) patients from Japan and Spain (the 172 A → T mutation (K5X) and the 46_72 deletion, respectively). The aim of our work was to evaluate the DNASE1 contribution in the genetic susceptibility of rheumatoid arthritis (RA, n = 151), Sjögren syndrome (SS, n = 55) and SLE (n = 34) in Tunisia. DNA from patients and healthy subjects (n = 232) were explored. Both reported mutations were absent among patient and control subjects. The DNASE1 exon2 sequence was analysed among 26 control subjects to identify new polymorphic variations that are possible. Five known SNPs were explored. The G/T transversion (rs8176927: R2S) was the most polymorphic functional nonsynonymous SNP. Using PCR-RFLP method, all DNAs were genotyped for rs8176927 for a case–control design. The statistical analysis showed no significant differences between patients and controls genotype data. In conclusion, our study showed, on the one hand, the absence of the K5X mutation and the 46_72 deletion in Tunisian patients affected with RA, SS and SLE and healthy subjects, and, on the other hand, the absence of association between the R2S polymorphism and the genetic susceptibility of RA, SS and SLE.

Keywords

Autoimmune diseases Deoxyribonuclease I Systemic lupus erythematosus Sjögren syndrome Rheumatoid arthritis 

List of abbreviations

AID

Autoimmune diseases

ANA

Anti-nuclear antibodies

DNASE1

Deoxyribonuclease 1

ds

Double strand

HETObs

Observed heterozygosity

PCR-RFLP

Polymerase chain reaction-restriction fragment length polymorphism

RA

Rheumatoid arthritis

SLE

Systemic lupus erythematosus

SNP

Single nucleotide polymorphism

SS

Sjögren syndrome

References

  1. 1.
    Yasuda T, Awazu S, Sato W et al (1990) Human genetically polymorphic deoxyribonuclease: purification, characterization, and multiplicity of urine deoxyribonuclease I. J Biochem 108:393–398PubMedGoogle Scholar
  2. 2.
    Rauch F, Polzar B, Stephan H et al (1997) Androgen ablation leads to an upregulation and intranuclear accumulation of deoxyribonuclease I in rat prostate epithelial cells paralleling their apoptic elimination. J Cell Biol 137:909–923. doi:10.1083/jcb.137.4.909 CrossRefPubMedGoogle Scholar
  3. 3.
    Mannherz HG, Peitsch MC, Zanotti S et al (1995) A new function for an old enzyme: the role of DNase I in apoptosis. Curr Top Microbiol Immunol 198:161–174PubMedGoogle Scholar
  4. 4.
    Lazarides E, Lindberg U (1974) Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc Natl Acad Sci USA 71:4742–4746. doi:10.1073/pnas.71.12.4742 CrossRefPubMedGoogle Scholar
  5. 5.
    Carroll MC (1998) The lupus paradox. Nat Genet 19:3–4. doi:10.1038/ng0598-3 CrossRefPubMedGoogle Scholar
  6. 6.
    Rosen A, Casciola-Rosen L (1999) Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 6:6–12. doi:10.1038/sj.cdd.4400460 CrossRefPubMedGoogle Scholar
  7. 7.
    Hermann M, Voll RE, Kalden JR (2000) Etiopathogenesis of systemic lupus erythematosus. Immunol Today 21:424–426. doi:10.1016/S0167-5699(00)01675-3 CrossRefGoogle Scholar
  8. 8.
    Tsukumo S, Yasutomo K (2004) DNaseI in pathogenesis of systemic lupus erythematosus. Clin Immunol 113:14–18. doi:10.1016/j.clim.2004.05.009 CrossRefPubMedGoogle Scholar
  9. 9.
    Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. doi:10.1002/art.1780400928 CrossRefPubMedGoogle Scholar
  10. 10.
    Wakeland EK, Liu K, Graham RR et al (2001) Delineating the genetic basis of systemic lupus erythematosus. Immunity 15:397–408. doi:10.1016/S1074-7613(01)00201-1 CrossRefPubMedGoogle Scholar
  11. 11.
    Ter Borg EJ, Horst G, Hummel EJ et al (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term prospective study. Arthritis Rheum 33:634–643. doi:10.1002/art.1780330505 CrossRefPubMedGoogle Scholar
  12. 12.
    Chitrabamrung S, Rubin RL, Tan EM (1981) Serum deoxyribonuclease 1 and clinical activities in systemic lupus erythematosus. Rheumatol Int 1:55–60. doi:10.1007/BF00541153 CrossRefPubMedGoogle Scholar
  13. 13.
    Macanovic M, Lachaman PJ (l997) Measurement of deoxyribonuclease 1 in the serum and urine of SLE-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 108:220–216. doi:10.1046/j.1365-2249.1997.3571249.x
  14. 14.
    Macanovic M, Sinicropi D, Shak S et al (1996) The treatment of systemic lupus erythematosus (SLE) in NZB/W F hybrid mice; studies with recombinant murine Dnase and with dexamenthasone. Clin Exp Immunol 106:243–252. doi:10.1046/j.1365-2249.1996.d01-839.x CrossRefPubMedGoogle Scholar
  15. 15.
    Verthelyi D, Dybdal N, Elias KA et al (1998) DNAse treatment does not improve the survival of lupus prone (NZB/NZW) F mice. Lupus 7:223–230. doi:10.1191/096120398678920037 CrossRefPubMedGoogle Scholar
  16. 16.
    Yasutomo K, Horiuchi T, Kagami S et al (2001) Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 28:313–314. doi:10.1038/91070 CrossRefPubMedGoogle Scholar
  17. 17.
    Simmonds MJ, Heward JM, Kelly MA et al (2002) A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves’ disease: comment on the article by Rood et al. Arthritis Rheum 46:3109–3110. doi:10.1002/art.10414 CrossRefPubMedGoogle Scholar
  18. 18.
    Chakraborty P, Hadj Kacem H, Makni-Karray K et al (2003) The A/T mutation in exon 2 of the DNASE1 gene is not present in Tunisian patients with systemic lupus erythematosus or in healthy subjects. Arthritis Rheum 48:3297–3298. doi:10.1002/art.11318 CrossRefPubMedGoogle Scholar
  19. 19.
    Liu MF, Wang CR, Fung LL (2004) No evidence of mutation in exon 2 of DNAse1 gene in Chinese patients with systemic lupus erythematosus. Lupus 13:142–143. doi:10.1191/0961203304lu478xx CrossRefPubMedGoogle Scholar
  20. 20.
    Balada E, Ordi-Ros J, Hernanz S et al (2002) DNASE I mutation and systemic lupus erythematosus in a Spanish population: comment on the article by Tew et al. Arthritis Rheum 46:1974–1976. doi:10.1002/art.10349 CrossRefPubMedGoogle Scholar
  21. 21.
    Bodano A, Amarelo J, Gonzalez A et al (2004) Novel DNASE I mutations related to systemic lupus Erythematosus. Arthritis Rheum 50:4070–4073. doi:10.1002/art.20721 CrossRefPubMedGoogle Scholar
  22. 22.
    Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277. doi:10.1002/art.1780251101 CrossRefPubMedGoogle Scholar
  23. 23.
    Kaplan G (1991) Syndrome de Gougerot-Sjögren. In: Kahn MF, Peltier AP, Meyer O, Piette JC (eds) Les maladies systémique, 2nd edn. Flammarion Médecine-Sciences, Paris, pp 499–544Google Scholar
  24. 24.
    Arnett FC, Edworthy SM, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria fort he classification of rheumatoid arthritis. Arthritis Rheum 31:315–324. doi:10.1002/art.1780310302 CrossRefPubMedGoogle Scholar
  25. 25.
    Kawazaki E (1990) Sample preparation from blood, cells and other fluids. In: Innis M, Gelffand D, Snisky G, White T (eds) PCR protocols. A guide to methods and application, 2nd edn. Academic Press, San Diego, pp 146–152Google Scholar
  26. 26.
    Vyse TJ, Kotzin BL (1998) Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 16:261–292. doi:10.1146/annurev.immunol.16.1.261 CrossRefPubMedGoogle Scholar
  27. 27.
    Davis P, Percy JS, Russell AS (1977) Correlation between levels of DNA antibodies and clinical disease activity in SLE. Ann Rheum Dis 36:157–159. doi:10.1136/ard.36.2.157 CrossRefPubMedGoogle Scholar
  28. 28.
    Swaak AJ, Groenwold J, Bronsveld W (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45:359–366. doi:10.1136/ard.45.5.359 CrossRefPubMedGoogle Scholar
  29. 29.
    Benucci M, Saviola G, Baiardi P et al (2008) Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. Clin Rheumatol 27:91–95. doi:10.1007/s10067-007-0728-5 CrossRefPubMedGoogle Scholar
  30. 30.
    Nardi N, Brito-Zerón P, Ramos-Casals M et al (2006) Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome, prevalence and clinical significance in 335 patients. Clin Rheumatol 25:341–346. doi:10.1007/s10067-005-0059-3 CrossRefPubMedGoogle Scholar
  31. 31.
    Rechlin M (1997) Systemic rheumatic diseases: undifferentiated connective tissue disease, overlap syndromes, and mixed connective tissue disease. In: Koopman WJ (ed) Arthritis and allied conditions a text book of rheumatology. William & Wilkins, Baltimore, pp 1445–1454Google Scholar
  32. 32.
    Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 14:111–124. doi:10.1053/berh.1999.0080 CrossRefPubMedGoogle Scholar
  33. 33.
    Jablonska S, Blaszczyk M (1999) Scleroderma overlap syndromes. Adv Exp Med Biol 455:85–92PubMedGoogle Scholar
  34. 34.
    Naiperi M, Karsunky H, Zevnik B et al (2000) Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25:177–181. doi:10.1038/76032 CrossRefGoogle Scholar
  35. 35.
    Shin HD, Park BL, Kim LH et al (2004) Common DNase I polymorphism associated with autoantibody production among systemic lupus erythematosus patients. Hum Mol Genet 13:2343–2350. doi:10.1093/hmg/ddh275 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Salima Belguith-Maalej
    • 1
  • Hassen Hadj-Kacem
    • 1
  • Neila Kaddour
    • 2
  • Zouhir Bahloul
    • 2
  • Hammadi Ayadi
    • 1
  1. 1.Unité Cibles pour le Diagnostic et la ThérapieCentre de Biotechnologie de SfaxSfaxTunisia
  2. 2.Service de Médecine interne, CHU Hédi-ChakerSfaxTunisia

Personalised recommendations